AstraZeneca plc  

(Public, LON:AZN)   Watch this stock  
Find more results for AZN
4,028.00
+5.50 (0.14%)
May 31 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 4,020.50 - 4,070.00
52 week 3,746.00 - 4,634.00
Open 4,040.00
Vol / Avg. 3.17M/2.21M
Mkt cap 50.87B*
P/E 25.53
Div/yield 131.00/4.68*
EPS 1.58*
Shares 1.26B
Beta     -
Inst. own     -
*GBP
Jul 28, 2016
Q2 2016 AstraZeneca PLC Earnings Release Add to calendar
Jul 6, 2016
AstraZeneca PLC IR Roadshow - Munich Add to calendar
Jul 5, 2016
AstraZeneca PLC IR Roadshow - Cologne, Stuttgart Add to calendar
Jun 21, 2016
AstraZeneca PLC at Citi European Healthcare Conference Add to calendar
Jun 8, 2016
AstraZeneca PLC at Jefferies Healthcare Conference Add to calendar
Apr 29, 2016
AstraZeneca PLC Annual Shareholders Meeting
Apr 29, 2016
Q1 2016 AstraZeneca PLC Earnings Call
Apr 29, 2016
Q1 2016 AstraZeneca PLC Earnings Release
Apr 26, 2016
Ironwood Pharmaceuticals Inc Enters into U.S. Licensing Agreement with AstraZeneca for Lesinurad Conference Call
Mar 31, 2016
AstraZeneca PLC at Bank of America Merrill Lynch Investor Relations Insights Conference
  

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 10.22% 11.44%
Operating margin 16.97% 16.65%
EBITD margin - 28.89%
Return on average assets 4.03% 4.76%
Return on average equity 15.59% 14.82%
Employees 61,500 -
CDP Score - 97 B

Address

- Legal Department, 2 Kingdom Street
LONDON, W2 6BD
United Kingdom - Map
+44-20-73045000 (Phone)
+44-20-76048151 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Officers and directors

Pascal Soriot Chief Executive Officer, Executive Director
Age: 56
Marc Dunoyer Chief Financial Officer, Executive Director
Age: 62
Fiona Cicconi Executive Vice-President, Human Resources
Sean Bohen M.D. Ph.D. Chief Medical Officer, Executive Vice President - Global Medicines Development
Ruud Dobber Executive Vice President, Europe
Paul Hudson President, AstraZeneca, US and Executive Vice-President, North America
Bahija Jallal Ph.D. Executive Vice President, MedImmune
Mark Mallon Executive Vice President, International
Luke Miels Executive Vice-President, GPPS
Menelas Pangalos Executive Vice President - Innovative Medicines